Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Guangdong Provincial People's Hospital.
Recruitment status was Active, not recruiting
Information provided by:
Guangdong Provincial People's Hospital
First received: April 17, 2008
Last updated: April 21, 2008
Last verified: April 2008
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was benefitted by first line chemotherapy. Patients with stage IV NSCLC who have one or more asymptomatic brain metastasis who was benefitted by first line chemotherapy will receive oral erlotinib 150mg once daily until disease progression or unacceptable toxicity. These patients' direct DNA sequencing of tumor tissue EGFR exons 18-21 will be analyzed The response was evaluated by RECIST criteria after the patient received erlotinib 6 weeks.If the patients present with progress disease of brain metastasis after the therapy of erlotinib, the patients will receive irradiation of brain metastasis.If the response is stable disease,partial response or complete response,he will be examined by brain MRI every 12 weeks.
Non-Small Cell Lung Cancer
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase II Study of Erlotinib in Benefitted Patients With Asymptomatic Brain Metastases Advanced Non-Small Cell Lung Cancer By Chemotherapy.
Primary Outcome Measures:
- Time of asymptomatic brain metastasis turn into symptomatic brain metastasis [ Time Frame: 3/2008~3/2011 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To determine objective response (CR+PR), time to progression, 6-month survival and 1-year survival,safety. [ Time Frame: 3/2008~3/2011 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2011 (Final data collection date for primary outcome measure)
non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
erlotinib 150mg qd until disease progression or unacceptable toxicity.
Other Name: TARVECA
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histological or cytological documented stage IV NSCLC. Sputum cytology alone is excluded
- Extracerebral lesions show stable disease after first line chemotherapy. Patient has recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or EGFR monoclonal antibody.
- Patients must be at least 18 years.
- ECOG Performance Status 0, 1 or 2.
- Life expectancy of at least 12 weeks.
- Appraisable disease, the presence of at least three lesions if longest diameter <10 mm by brain MRI.
- Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x 109/L, platelets ³ 100 x 109/L.
- Total bilirubin £ 1.5 x upper limit of normal (ULN)
- ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver metastases.
- Creatinine clearance ³ 60ml/min (calculated according to Cockcroft-gault formula).
- PT-INR/PTT < 1.2 x ULN.
- Written informed consent.
- Able to comply with study and follow-up procedures.
- Mixed small cell and non-small cell lung cancer histology.
- Any unresolved toxicity>CTCAE grade 2 from previous anti-cancer therapy.
- Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.
- Other concurrent anticancer therapy.
- Patients with exposure to investigational drug therapy outside of this trial.
- Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.
- Any unstable systemic disease (including active infection, hepatic, renal, metabolic disease or seizure disorder requiring medication).
- Significant cardiovascular event: congestive heart failure >NYHA class 2; unstable angina, active CAD (myocardial infarction more than 1 year prior to study entry is allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers or digoxin are permitted) or uncontrolled hypertension.
- Brain metastases or spinal cord compression, if treated before the start of study treatment, and have any symptoms. Symptoms include signs of increased intracranial pressure ,headache,nausea and vomiting,cognitive or affective disturbances,seizures,and focal neurologic symptoms.
- History of another malignancy within the last 5 years except cured carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors [Ta, Tis & T1].
- Pregnant or breast-feeding women.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00663689
Guangdong Provincial People's Hospital
||Wu Yilong, MD
||Cancer center of Guangdong PPH
No publications provided
||Yilong,Wu, Guangdong Provincial People's Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 17, 2008
||April 21, 2008
||United States: Institutional Review Board
Keywords provided by Guangdong Provincial People's Hospital:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 31, 2015
Carcinoma, Non-Small-Cell Lung
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors